Clinical Trials Browser

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

Prostatic Neoplasms

Breast Neoplasms, Triple Negative Breast Neoplasms

Biliary Tract Neoplasms, Neoplasm Metastasis

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Small Cell Lung Carcinoma

Fallopian Tube Neoplasms, Ovarian Neoplasms

Small Cell Lung Carcinoma

Prostate Cancer Metastatic

Breast Neoplasms

Breast Neoplasms

Uterine Cervical Neoplasms, Endometrial Neoplasms

Breast Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms

Metastatic Castration Resistant Prostate Cancer

Pancreatic Neoplasms

Fallopian Tube Neoplasms, Ovarian Neoplasms, Recurrence

Fallopian Tube Neoplasms, Ovarian Neoplasms

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms, Recurrence

Advanced Gastric Cancer

Mental Retardation, X-Linked, With Or Without Seizures, Arx-Related

Advanced Solid Tumor

Advanced Solid Tumors

Breast Neoplasms

Genital Neoplasms, Female

Carcinoma, Ovarian Epithelial, Breast Neoplasms, Ovarian Neoplasms

Clinical Trials

Analysis of the Clinical Experience With Rucaparib in the Rucaparib Access Program (RAP) in Spain - A GEICO Study

CheckMate 9KD

A Study of Rucaparib Administered With Radiation in Patients With Triple Negative Breast Cancer With an Incomplete Response Following Chemotherapy

Rucaparib in Combination With Nivolumab in Patients With Advanced or Metastatic Biliary Tract Cancer Following Platinum Therapy

Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)

PLX038 (PEGylated SN38) and Rucaparib in Solid Tumors and Small Cell Cancers

Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants With Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Combination Rucaparib With Nivolumab in Small Cell Lung Carcinoma

TRIUMPH

Window of Opportunity Trial, PARP Inhibitor Rucaparib Affect on PD-L1 Expression in Triple Negative Breast Tumors

PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 Mutations

Clovis-001

A Study Evaluating the Safety, Pharmacokinetics and Efficacy of Ipatasertib Administered in Combination With Rucaparib in Participants With Advanced Breast, Ovarian Cancer, and Prostate Cancer.

RAMP

A Study of Rucaparib in Patients With Pancreatic Cancer and a Known Deleterious BRCA Mutation

A Study of Oral Rucaparib in Patients With a Solid Tumor (Phase I) or With gBRCA Mutation Ovarian Cancer (Phase II)

ARIEL3

ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients

FRACTION-GC

TRITON2

A Study of Rucaparib in Japanese Patients With a Previously-treated Solid Tumor

Rucaparib Hepatic Impairment Study in Patients With a Solid Tumor

A Study Of Poly (ADP-Ribose) Polymerase Inhibitor PF-01367338 In Combination With Several Chemotherapeutic Regimens

Drug-Drug Interaction Study of Rucaparib, Rosuvastatin and Oral Contraceptives

Arterial Hypertension Related to PARP Inhibitors (ArteRIB)

Pancytopenia Related to PARP Inhibitors (PancytoRIB)

RUBY

A Combination Study of Rucaparib and Atezolizumab in Participants With Advanced Gynecologic Cancers and Triple-Negative Breast Cancer

Rucaparib(CO-338;Formally Called AG-014699 or PF-0136738) in Treating Patients With Locally Advanced or Metastatic Breast Cancer or Advanced Ovarian Cancer